Skip to main content

RNAZ

Stock
Health Care
Biotechnology

Performance overview

RNAZ Price
Price Chart

Forward-looking statistics

Beta
0.68
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

transcode therapeutics is a boston based pre-clinical biopharmaceutical company focused on discovery, development and commercialization of a pipeline of innovative microrna (mirnas or mirs) therapeutics for treating metastatic disease.

Company info

SectorHealth Care
IndustryBiotechnology
Employees13
Market cap$7.3M

Fundamentals

Enterprise value-$5.1M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$792.40
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$449K
Avg trading volume (10 day)$302K
Put-call ratio

Macro factor sensitivity

Growth-11.5
Credit+2.1
Liquidity+0.6
Inflation+0.6
Commodities+4.0
Interest Rates+1.4

Valuation

Dividend yield0.00%
PEG Ratio-14.33
Price to sales
P/E Ratio-14.33
Enterprise Value to Revenue
Price to book0.70

Upcoming events

Next earnings dayApril 2, 2024
Next dividend day
Ex. dividend day

News

All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy

TransCode Therapeutics (RNAZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (April 18, 2025)
Why Are TransCode Therapeutics Shares Shooting Higher On Thursday?

TransCode Therapeutics Inc (NASDAQ: RNAZ) is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology.  Related:   TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development.

Benzinga (September 23, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free